Recent News

• 04.16.2025 - Encore Presentation: Inhaled Molgramostim for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) – Results from the IMPALA-2 Phase 3 Clinical Trial
• 04.10.2025 - Encore Presentation: Inhaled Molgramostim Improves Pulmonary Gas Exchange, Quality of Life, and Exercise Capacity in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
• 01.29.2025 - Long-Term Outcomes in Five Patients with Autoimmune Pulmonary Alveolar Proteinosis Treated with Molgramostim Inhalation Solution

Recent Filings

• 04.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.31.2025 - 8-K Current report
• 03.27.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 03.27.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.26.2025 - 8-K Current report
• 03.26.2025 - EX-99.1 EX-99.1
• 03.21.2025 - 3 Initial statement of beneficial ownership of securities
• 02.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.11.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors